Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of SAR442168 in relapsing multiple sclerosis
2018-003927-12Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing SAR442168 dose-finding arms with Placebo (2 arms). Primary endpoint: Number of new Gd-enhancing T1 hyperintense lesions. Started Jan 2019; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-003927-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003927-12.